PULM - ポルメイトリックス (Pulmatrix Inc.)

PULMのニュース

   Pulmatrix Reports Q2 2020 Results and Business Updates  2020/08/07 13:00:00 PR Newswire
LEXINGTON, Mass., Aug. 7, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today reports its Q2 2020…
   Pulmatrix Announces Progress by Sensory Cloud Toward Commercial Launch of FEND in Fall 2020, an OTC Nasal Hygiene Product Designed to Suppress Exhaled Airborne Particles  2020/07/08 12:30:00 PR Newswire
LEXINGTON, Mass., July 8, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, announced that Sensory Cloud, which…
   Pulmatrix Announces Changes to Board of Directors  2020/06/26 13:00:00 PR Newswire
LEXINGTON, Mass., June 26, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, announced upcoming changes to its Board…
   Pulmatrix to Host 2020 Annual Meeting of Stockholders Virtually  2020/05/27 13:00:00 PR Newswire
LEXINGTON, Mass., May 27, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that, due to…
   The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive  2020/05/21 12:01:32 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Ascendis Pharma A/S (NASDAQ: ASND ) (announced first-quarter results) Altimmune Inc (NASDAQ: ALT ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cue Biopharma Inc (NASDAQ: CUE ) (reacted to first-quarter results) Evoke Pharma Inc (NASDAQ: EVOK ) (announced FDA's conditional approval for the brand name Gimoti for its nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis) GENMAB A/S/S ADR (NASDAQ: GMAB ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Novo Nordisk A/S (NYSE: NVO ) PDL BioPharma Inc (NASDAQ: PDLI ) Pulmatrix Inc (NASDAQ: PULM ) Qiagen NV (NYSE: QGEN ) Soleno Therapeutics Inc (NASDAQ: SLNO ) Surface Oncology Inc (NASDAQ: SURF ) - announced an oncology partnership with Merck & Co., Inc. (NYSE: MRK ) VBI Vaccines Inc (NASDAQ: VBIV ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) (announced $20-million Series A financing to establish a Chinese joint venture) Down In The Dumps (Biotech stocks that hit 52-week lows on May 20.) Genfit SA (NASDAQ: GNFT ) RA Medical Systems Inc (NYSE: RMED ) (priced its 22.22-million-share common stock offering at 45 cents per share) Stocks In Focus Gilead-Galapagos Drug Produces Mixed Results In Ulcerative Colitis Study Gilead Sciences, Inc. (NASDAQ: GILD ) and GALAPAGOS NV/S ADR (NASDAQ: GLPG ) announced top-line results from the Phase 2b/3 trial evaluating the efficacy and safety of filgotinib in adult patients with moderately to severely active ulcerative colitis showing mixed results.
   Pulmatrix to Host 2020 Annual Meeting of Stockholders Virtually  2020/05/27 13:00:00 PR Newswire
LEXINGTON, Mass., May 27, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that, due to…
   The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive  2020/05/21 12:01:32 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Ascendis Pharma A/S (NASDAQ: ASND ) (announced first-quarter results) Altimmune Inc (NASDAQ: ALT ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cue Biopharma Inc (NASDAQ: CUE ) (reacted to first-quarter results) Evoke Pharma Inc (NASDAQ: EVOK ) (announced FDA's conditional approval for the brand name Gimoti for its nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis) GENMAB A/S/S ADR (NASDAQ: GMAB ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Novo Nordisk A/S (NYSE: NVO ) PDL BioPharma Inc (NASDAQ: PDLI ) Pulmatrix Inc (NASDAQ: PULM ) Qiagen NV (NYSE: QGEN ) Soleno Therapeutics Inc (NASDAQ: SLNO ) Surface Oncology Inc (NASDAQ: SURF ) - announced an oncology partnership with Merck & Co., Inc. (NYSE: MRK ) VBI Vaccines Inc (NASDAQ: VBIV ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) (announced $20-million Series A financing to establish a Chinese joint venture) Down In The Dumps (Biotech stocks that hit 52-week lows on May 20.) Genfit SA (NASDAQ: GNFT ) RA Medical Systems Inc (NYSE: RMED ) (priced its 22.22-million-share common stock offering at 45 cents per share) Stocks In Focus Gilead-Galapagos Drug Produces Mixed Results In Ulcerative Colitis Study Gilead Sciences, Inc. (NASDAQ: GILD ) and GALAPAGOS NV/S ADR (NASDAQ: GLPG ) announced top-line results from the Phase 2b/3 trial evaluating the efficacy and safety of filgotinib in adult patients with moderately to severely active ulcerative colitis showing mixed results.
   Pulmatrix Reports Q1 2020 Results  2020/05/14 13:00:00 PR Newswire
LEXINGTON, Mass., May 14, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology today reports its Q1 2020…
   Pulmatrix : 4/A | MarketScreener  2020/05/14 12:45:23 MarketScreener
SEC Form 4 FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5… | May 14, 2020
   Pulmatrix : DEF 14A | MarketScreener  2020/05/14 12:35:21 MarketScreener
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 … | May 14, 2020
   Pulmatrix Reports Q1 2020 Results  2020/05/14 13:00:00 PR Newswire
LEXINGTON, Mass., May 14, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology today reports its Q1 2020…
   Pulmatrix : 4/A | MarketScreener  2020/05/14 12:45:23 MarketScreener
SEC Form 4 FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5… | May 14, 2020
   Pulmatrix : DEF 14A | MarketScreener  2020/05/14 12:35:21 MarketScreener
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 … | May 14, 2020
   United States Long-Acting Bronchodilator Market (2019 to 2025) - Featuring AstraZeneca, Novartis & Pulmatrix Among Others - ResearchAndMarkets.com  2020/04/29 14:58:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "US Long-Acting Bronchodilator Market 2019-2025" report has been added to ResearchAndMarkets.com's offering. The US long-acting bronchodilator market is anticipated to grow at a substantial rate of 1.7% during the forecast period. The growth of the market of long-acting bronchodilator devices in the US is mainly driven by factors that include the growing prevalence of chronic diseases such as asthma, diabetes, respiratory lung diseases and so on. Asthma is chronic i
   The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement  2020/04/17 11:35:23 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 16.) Abbott Laboratories (NYSE: ABT ) (reacted to first-quarter results and an announcement concerning development of a third rapid COVID-19 screening test) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Chembio Diagnostics Inc (NASDAQ: CEMI ) DexCom, Inc. (NASDAQ: DXCM ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Eli Lilly And Co (NYSE: LLY ) Immunovant Inc (NASDAQ: IMVT ) Masimo Corporation (NASDAQ: MASI ) Moderna Inc (NASDAQ: MRNA ) Novavax, Inc. (NASDAQ: NVAX ) (its Australian developmental partner said COVID-19 vaccine human testing will begin in the coming weeks) OraSure Technologies, Inc. (NASDAQ: OSUR ) Pulmatrix Inc (NASDAQ: PULM ) (granted Sensory Cloud license to its PUR 003 and PUR 006) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) (announced FDA acceptance of BLA for REGN-EB3, a triple antibody cocktail treatment for Ebola virus infection, with Priority Review designation) Seattle Genetics, Inc. (NASDAQ: SGEN ) Thermogenesis Holdings Inc (NASDAQ: THMO ) (announced FDA concurrence that its COVID-19 antibody blood test has been properly validated and can now be distributed) Down In The Dumps (Biotech stocks that hit 52-week lows April 16) AxoGen, Inc Common Stock (NASDAQ: AXGN ) Celcuity Inc (NASDAQ: CELC ) Stocks In Focus Moderna Obtains $483M In BARDA Funding For COVID-19 Vaccine Research Moderna said the Biomedical Advanced Research and Development Authority, or BARDA, has committed up to $483 million in funding to accelerate the development of its mRNA vaccine against the novel coronavirus — SARS-CoV-19.

calendar